Safety and Efficacy of Universal CD19-targeting CAR-γδT Cells in Refractory Autoimmune Diseases

PHASE1/PHASE2RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

July 1, 2025

Primary Completion Date

December 31, 2027

Study Completion Date

December 31, 2027

Conditions

Systemic Lupus ErthematosusSystemic Sclerosis (SSc)Sjogren SyndromeANCA Associated Vasculitis (AAV)Inflammatory MyopathiesAntiphospholipid Syndrome

Interventions

BIOLOGICAL

anti-CD19 CAR T cell therapy

anti-CD19 CAR-γδ T cell therapy

Trial Locations (1)

RECRUITING

Peking University Third Hospital, Beijing

All Listed Sponsors

lead

Peking University Third Hospital

OTHER

NCT06828042 - Safety and Efficacy of Universal CD19-targeting CAR-γδT Cells in Refractory Autoimmune Diseases | Biotech Hunter | Biotech Hunter